Matsubayashi K, Shintani S, Yoshida K, Yamada M, Tachizawa H
Exploratory Research Laboratories I, Tokyo Research and Development Center, Daiichi Pharmaceutical Company, Ltd., Japan.
J Pharm Sci. 1994 Feb;83(2):186-92. doi: 10.1002/jps.2600830214.
The pharmacokinetics and its dose dependency of a new cephalosporin, DQ-2556, were studied in the rat and rabbit. The pharmacokinetics of the compound in the rat was linear up to a dose of 300 mg/kg; however, at a dose of 1200 mg/kg, renal clearance decreased dramatically and the normalized area under the blood concentration-time curve increased remarkably. On the other hand, there were no dose-dependent changes in tissue/serum concentration ratios, serum protein binding, red cell binding, and the distribution of DQ-2556. In the rabbit, the pharmacokinetics of DQ-2556 was linear even up to a dose of 1200 mg/kg and no unusual pharmacokinetic behavior was observed. The renal clearance experiments demonstrated that DQ-2556 is excreted by glomerular filtration. It was also shown that the glomerular filtration rate (GFR) remained constant up to a dose of 1000 mg/kg of DQ-2556 in the rat, whereas the GFR decreased by 95.1% at a dose of 1200 mg/kg. The coincidence of dose relationship and species difference in the disorder of GFR and renal toxicity suggests that the change of pharmacokinetics of DQ-2556 was caused by its renal toxic effects at very high dose.
在大鼠和兔子身上研究了新型头孢菌素DQ - 2556的药代动力学及其剂量依赖性。该化合物在大鼠体内,剂量达300mg/kg时药代动力学呈线性;然而,在1200mg/kg剂量时,肾脏清除率显著下降,血药浓度-时间曲线下归一化面积显著增加。另一方面,DQ - 2556的组织/血清浓度比、血清蛋白结合、红细胞结合及分布不存在剂量依赖性变化。在兔子身上,即使剂量高达1200mg/kg,DQ - 2556的药代动力学仍呈线性,未观察到异常的药代动力学行为。肾脏清除实验表明,DQ - 2556通过肾小球滤过排泄。研究还表明,在大鼠中,剂量达1000mg/kg的DQ - 2556时肾小球滤过率(GFR)保持恒定,而在1200mg/kg剂量时GFR下降了95.1%。GFR紊乱和肾脏毒性中剂量关系与物种差异的一致性表明,DQ - 2556药代动力学的变化是由其极高剂量下的肾脏毒性作用引起的。